Mayne Pharma
(ASX:MYX) has acquired US and Australian rights to halobetasol foam – a dermatological product for treating psoriasis for an investment of US$32 million.
Psoriasis is the most prevalent autoimmune disease in the US which affects over 7.5 million Americans each year.
The foam has a market value at US$64 million and growing 10 per cent per annum in volume terms.
It was approved by US FDA in May 2018.
